NGS test completed in one day, lung and colon cancer test kits receive FDA approval
NGS (next generation sequencing technology), also known as high-throughput sequencing technology. It is commonly used for genetic disease screening, prenatal testing or diagnosis, oncology clinical diagnosis, pharmacogenomic testing, cancer chemotherapy and treatment, and single gene disease screening or diagnosis. It is capable of sequencing hundreds of thousands to millions of DNA molecules in parallel at one time, with fast analysis speed, high accuracy, and short time.
NGS testing is currently used in clinical settings to evaluate the availability of appropriate immunotherapeutic agents or targeted drugs, and to test patients with a family history of genetic tumors and both parents or close relatives to determine the type of genetic disease, to test relatives for disease, to assess the risk of disease, and to assess the risk to the reproductive system.
Pillar Biosciences is a global oncology precision diagnostic solutions company, but its NGS tests are unrelated to the NGS testing platform. The company has developed SLIMamp® and PiVAT® using AI technology to reduce traditional NGS testing time from days to one day, and requires less DNA quantity to provide valid test results even if the test sample is damaged.
Source: https://www.vbdata.cn/1518859894
Related Posts
Laekna HK$791 million IPO
We advised Laekna on its IPO and HKEX listing Davis Polk advised Laekna, Inc. in connection with its initial public offering and listing on the Hong Kong Stock Exchange and an international offering in reliance on Regulation S. The net proceeds from the offering amounted to approximately HK$791 million. Founded in 2016, Laekna, Inc. is […]
Yizhu Technology Completes Multi-Hundred-Million RMB Financing to Drive AI Chip Innovation （October 15, 2024)
Yizhu Technology announced completion of multi-hundred-million RMB financing led by a renowned overseas fund with participation from Shengshi Technology and Xingzhi Capital. The funding will support ongoing development and innovation of AI compute chips and system solutions, focusing on overcoming the “memory wall” and “energy wall” for
Based on the SIPS model ChangYi proposes marketing strategies for big health brands
According to the “Gen Z Nutrition Consumption Trend Report,” consumers aged 18-35 account for 83.7% of the total health and wellness market, becoming the main force driving growth. Driven by the “Healthy China” initiative and shifting health awareness, the industry is rapidly developing amid fierce competition. Marketing focus has shifte
Unveiled the “Shushan” cryogenic CMOS quantum control chipset (March, 2025)
Unveiled the “Shushan” cryogenic CMOS quantum control chipset, including “Gongga” (superconducting qubit control), “Emei” (qubit readout), and “Xiling” (silicon-based qubit control) chips. “Xiling” was presented at ISSCC 2025, reducing system noise and power consumption for large-scale qubit arrays. Ne
Leave a Reply